[HTML][HTML] Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review
D Pascual-Figal, A Bayés-Genis… - Frontiers in …, 2021 - frontiersin.org
Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited
exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high …
exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high …
Sacubitril/valsartan in heart failure: latest evidence and place in therapy
E Kaplinsky - Therapeutic advances in chronic disease, 2016 - journals.sagepub.com
Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at
high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is …
high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is …
Dual angiotensin receptor and neprilysin inhibition with sacubitril/valsartan in chronic systolic heart failure: understanding the new PARADIGM
MP Lillyblad - Annals of Pharmacotherapy, 2015 - journals.sagepub.com
Objective: To evaluate the clinical role of sacubitril/valsartan, a novel angiotensin–neprilysin
inhibitor, for the treatment of chronic heart failure with a reduced ejection fraction (HFrEF) …
inhibitor, for the treatment of chronic heart failure with a reduced ejection fraction (HFrEF) …
[HTML][HTML] Reviewing the modern therapeutical options and the outcomes of sacubitril/valsartan in heart failure
Sacubitril/valsartan (S/V) is a pharmaceutical strategy that increases natriuretic peptide
levels by inhibiting neprilysin and regulating the renin-angiotensin-aldosterone pathway …
levels by inhibiting neprilysin and regulating the renin-angiotensin-aldosterone pathway …
Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF
KF Docherty, M Vaduganathan, SD Solomon… - Heart Failure, 2020 - jacc.org
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to
reduce the risk of cardiovascular death or heart failure hospitalization and improve …
reduce the risk of cardiovascular death or heart failure hospitalization and improve …
The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
E Gronda, E Vanoli, M Iacoviello - European Heart Journal …, 2020 - academic.oup.com
Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical condition
characterized by large pathophysiology heterogeneity with lack of effective therapies as …
characterized by large pathophysiology heterogeneity with lack of effective therapies as …
[HTML][HTML] Practical guidance on the use of sacubitril/valsartan for heart failure
Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has
been recommended in clinical practice guidelines to reduce morbidity and mortality in …
been recommended in clinical practice guidelines to reduce morbidity and mortality in …
The efficacy and safety of sacubitril/valsartan in heart failure patients: a review
R Zhang, X Sun, Y Li, W He, H Zhu… - Journal of …, 2022 - journals.sagepub.com
Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …
Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
A Abdin, M Schulz, U Riemer, B Hadëri… - ESC heart …, 2022 - Wiley Online Library
Heart failure (HF) treatment has changed substantially over the last 30 years, leading to
significant reductions in mortality and hospital admissions in patients with HF with reduced …
significant reductions in mortality and hospital admissions in patients with HF with reduced …
相关搜索
- heart failure sacubitril valsartan
- ejection fraction sacubitril valsartan
- ejection fraction heart failure
- neprilysin inhibition sacubitril valsartan
- clinical benefits sacubitril valsartan
- clinical benefits heart failure
- paragon hf sacubitril valsartan
- paragon hf heart failure
- clinical benefits ejection fraction
- paragon hf ejection fraction
- latest evidence sacubitril valsartan
- angiotensin receptor sacubitril valsartan
- neprilysin inhibition heart failure
- latest evidence heart failure
- angiotensin receptor heart failure
- patient selection sacubitril valsartan